CLAIMS

1. An antibody for use in the treatment of rheumatoid arthritis in a subject in need thereof, wherein,
   (i) the subject has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months, and does not have anemia; and
   (ii) the antibody is to be administered at
      a. 162 mg of tocilizumab once per week subcutaneously to the subject; or
      b. 8 mg/kg of tocilizumab once every 4 weeks intravenously to the subject.

2. An antibody for use in the treatment of rheumatoid arthritis in a subject in need thereof, wherein
   (i) the subject has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months, and is from 18 to 34 years old; and
   (ii) the antibody is to be administered at
      a. 162 mg of tocilizumab once per week subcutaneously to the subject; or
      b. 8 mg/kg of tocilizumab once every 4 weeks intravenously to the subject.

3. An antibody for use in the treatment of rheumatoid arthritis in a subject in need thereof, wherein
   (i) the subject has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months, and has not been administered a corticosteroid within 90 days; and
   (ii) the antibody is to be administered at
      a. 162 mg of tocilizumab once per week subcutaneously to the subject; or
      b. 8 mg/kg of tocilizumab once every 4 weeks intravenously to the subject.

4. An antibody for use in the treatment of rheumatoid arthritis in a subject in need thereof, wherein
   (i) the subject has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months, and has depression; and

(ii) the antibody is to be administered at

a. 162 mg of tocilizumab once per week subcutaneously to the subject; or

b. 8 mg/kg of tocilizumab once every 4 weeks intravenously to the subject.

5. The antibody for use according to any one of claims 1-4, wherein the antibody is to be administered at 162 mg of tocilizumab once per week subcutaneously to the subject.

6. The antibody for use according to any one of claims 1-5, wherein the antibody is to be administered at 8 mg/kg of tocilizumab once every 4 weeks intravenously to the subject.

7. The antibody for use according to any one of claims 1-6, wherein the subject has moderately-to-severely active rheumatoid arthritis.

8. The antibody for use according to any one of claims 1-7, wherein the subject has not been administered with sarilumab.

9. The antibody for use according to any one of claims 1-8, wherein the subject weighs less than 100 kg.

10. The antibody for use according to any one of claims 1-9, wherein the subject does not have ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, ulcerative colitis, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, or giant-cell arteritis.

11. The antibody for use according to any one of claims 1, 2, and 5-10, wherein the subject does not have anemia and is from 18 to 34 years old.

12. The antibody for use according to any one of claims 1, 3, and 5-10, wherein the subject does not have anemia and has not been administered with a corticosteroid within 90 days.

13. The antibody for use according to any one of claims 1, 2, and 5-10, wherein the subject is from 18 to 34 years old and has not been administered with a corticosteroid within 90 days.

14. The antibody for use according to any one of claims 1-3 and 5-10, wherein the subject does not have anemia, has not been administered with a corticosteroid within 90 days, and is from 18 to 34 years old.

15. The antibody for use according to any one of claims 1 and 4-10, wherein the subject does not have anemia and has depression.

16. The antibody for use according to any one of claims 3-10, wherein the subject has depression and has not been administered with a corticosteroid within 90 days.

17. The antibody for use according to any one of claims 2 and 4-10, wherein the subject is from 18 to 34 years old and has depression.

18. The antibody for use according to any one of claims 1, 2, and 4-10, wherein the subject does not have anemia, has depression and is from 18 to 34 years old.

19. The antibody for use according to any one of claims 1 and 4-10, wherein the subject does not have anemia, has depression, and has not been administered with a corticosteroid within 90 days.

20. The antibody for use according to any one of claims 1, 2, and 4-10, wherein the subject is from 18 to 34 years old, has depression, and has not been administered with a corticosteroid within 90 days.

21. The antibody for use according to any one of claims 1-20, wherein the subject with does not have anemia, has not been administered with a corticosteroid within 90 days, is from 18 to 34 years old, and has depression.

22. The antibody for use according to any one of claims 3, 5-10, 12, 13, 14, 16, and 19-20, wherein the within 90 days is within 90 days of the subject's first administration of tocilizumab.

23. The antibody for use according to any one of claims 3, 5-10, 12, 13, 14, 16, and 19-22, wherein the corticosteroid is prednisone.

24. The antibody for use according to any one of claims 1-23, wherein the subject is not administered with any other DMARD in course of administration with tocilizumab.

25. The antibody ritis according to any one of claims 1-23, wherein the subject is also administered with one or more additional DMARDs with tocilizumab.

26. The antibody for use according to claim 25, wherein the one or more additional DMARDs comprise methotrexate.

27. The antibody for use according to any one of claims 1-26, wherein the subject previously had an inadequate response to a conventional synthetic DMARD or a biologic DMARD.

28. The antibody for use according to claim 27, wherein the conventional synthetic DMARD is methotrexate.

29. The antibody for use according to claim 27, wherein the biologic DMARD is a TNFα inhibitor.

30. The antibody for use according to claim 29, where the TNFα inhibitor is adalimumab.

31. The antibody for use according to any one of claims 1-30, wherein the subject has not previously been administered with tocilizumab.

32. The antibody for use according to any one of claims 1-30, wherein the subject has been administered with tocilizumab for less than three months.

33. The antibody for use according to claim 32, wherein the subject has been administered with tocilizumab for less than two months.

34. The antibody for use according to claim 32, wherein the subject has been administered with tocilizumab for less than one month.

35. The antibody for use according to any one of claims 1-35, wherein the subject is female.

36. Use of a tocilizumab in the manufacture of a medicament for treating rheumatoid arthritis, wherein said tocilizumab is to be administered to a subject who has not previously been administered with tocilizumab or who has been administered with tocilizumab for less than three months, and does not have anemia, and wherein the tocilizumab is to be administered as follows:

    a. 162 mg of tocilizumab once per week to the subject, wherein the tocilizumab is administered subcutaneously; or
    b. 8 mg/kg of tocilizumab once every 4 weeks to the subject, wherein the tocilizumab is administered intravenously.

37. Use of a tocilizumab in the manufacture of a medicament for treating rheumatoid arthritis, wherein said tocilizumab is to be administered to a subject who has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months, and who is from 18 to 34 years old, and wherein the tocilizumab is to be administered as follows:

    a.162 mg of tocilizumab once per week to the subject, wherein the tocilizumab is administered subcutaneously; or
    b. 8 mg/kg of tocilizumab once every 4 weeks to the subject, wherein the tocilizumab is administered intravenously.

38. Use of a tocilizumab in the manufacture of a medicament for treating rheumatoid arthritis, wherein said tocilizumab is to be administered to a subject who has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months, and has not been administered with a

corticosteroid within 90 days; and wherein the tocilizumab is to be administered as follows:

a. 162 mg of tocilizumab once per week to the subject, wherein the tocilizumab is administered subcutaneously; or
b. 8 mg/kg of tocilizumab once every 4 weeks to the subject, wherein the tocilizumab is administered intravenously.

.

39. Use of a tocilizumab in the manufacture of a medicament for treating rheumatoid arthritis, wherein said tocilizumab is to be administered to a subject who has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months, and has depression, and wherein the tocilizumab is to be administered as follows:

a. 162 mg of tocilizumab once per week to the subject, wherein the tocilizumab is administered subcutaneously; or
b. 8 mg/kg of tocilizumab once every 4 weeks to the subject, wherein the tocilizumab is administered intravenously.

40. The use of any one of claims 36-39, wherein the subject has moderately-to-severely active rheumatoid arthritis.

41. The use of any one of claims 36-40, wherein the subject has not been administered with sarilumab.

42. The use of any one of claims 36-41, wherein the subject weighs less than 100 kg.

43. The use of any one of claims 36-42, wherein the subject does not have ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, ulcerative colitis, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, or giant-cell arteritis.

44. The use of any one of claims 36, 37, and 40-43, wherein the subject is selected if the subject does not have anemia and is from 18 to 34 years old.

45. The use of any one of claims 36, 38, and 40-43, wherein the subject is selected if the subject does not have anemia and has not been administered a corticosteroid within 90 days.

46. The use of any one of claims 36, 37, and 40-43, wherein the subject is selected if the subject is from 18 to 34 years old and has not been administered a corticosteroid within 90 days.

47. The use of any one of claims 36, 37and 39-43, wherein the subject is selected if the subject does not have anemia, has not been administered a corticosteroid within 90 days, and is from 18 to 34 years old.

48. The use of any one of claims 36 and 39-43, wherein the subject is selected if the subject does not have anemia and has depression.

49. The use of any one of claims 38-43, wherein the subject is selected if the subject has depression and has not been administered a corticosteroid within 90 days.

50. The use of any one of claims 37 and 39-43, wherein the subject is selected if the subject is from 18 to 34 years old and has depression.

51. The use of any one of claims 36, 37, and 39-43, wherein the subject is selected if the subject does not have anemia, has depression and is from 18 to 34 years old.

52. The use of any one of claims 36 and 39-43, wherein the subject is selected if the subject does not have anemia, has depression, and has not been administered a corticosteroid within 90 days.

53. The use of any one of claims 36, 37, and 39-43, wherein the subject is selected if the subject is from 18 to 34 years old, has depression, and has not been administered a corticosteroid within 90 days.

54. The use of any one of claims 36-53, wherein the subject is selected if the subject does not have anemia, has not been administered a corticosteroid within 90 days, is from 18 to 34 years old, and has depression.

55. The use of any one of claims 38, 40- 43, 45, 46, 47, 49, and 52-53, wherein the within 90 days is within 90 days of the subject's first administration of tocilizumab.

56. The use of any one of claims 38, 40-43, 45, 46, 47, 49, and 52-53, wherein the within 90 days is within 90 days of the selection.

57. The use of any one of claims 38, 40-43, 45, 46, 47, 49, and 52-53, wherein the corticosteroid is prednisone.

58. The use of any one of claims 36-57, wherein the subject is not to be administered with any other DMARD in course of administration with tocilizumab.

59. The use of any one of claims 36-57, wherein the subject is to be administered with one or more additional DMARDs with tocilizumab.

60. The use of claim 59, wherein the one or more additional DMARDs comprise methotrexate.

61. The use of any one of claims 36-60, wherein the subject previously had an inadequate response to a conventional synthetic DMARD or a biologic DMARD.

62. The use of claim 61, wherein the conventional synthetic DMARD is methotrexate.

63. The use of claim 61, wherein the biologic DMARD is a TNFα inhibitor.

64. The use of claim 63, where the TNFα inhibitor is adalimumab.

65. The use of any one of claims 36-64, wherein the subject has not previously been administered with tocilizumab.

66. The use of any one of claims 36-64, wherein the subject has been administered with tocilizumab for less than three months.

67. The use of claim 64, wherein the subject has been administered with tocilizumab for less than two months.

68. The use of claim 64, wherein the subject has been administered with tocilizumab for less than one month.

69. The use of any one of claims 36-68, wherein the subject is female.